Galapagos NV announced that the research site in Zagreb, Croatia, will form the basis of a newly created service division, called Fidelta. Fidelta is an exciting new drug discovery service company, being launched in the year that Croatia joins the European Union. Fidelta will be led by Phil Dudfield, who has extensive experience in drug discovery within large pharma and Galapagos and 5 years running fee-for-service groups at BioFocus.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.02 EUR | 0.00% |
|
+7.94% | -32.36% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.36% | 1.8B | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- GLPG Stock
- News Galapagos NV
- Galapagos NV Creates Fidelta, a Third Galapagos Service Division